Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Revenue: US$2.77b (up 12% from 3Q 2023). Net income: US$1.05b (up 1.0% from 3Q 2023). Profit margin: 38% (down from 42% in 3Q 2023). EPS: US$4.05 (up from US$4.01 in 3Q 2023). Revenue exceeded ...

This page features the latest news about the Vertex Pharmaceuticals DRC stock. Vertex Pharma to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...